Insider Monkey
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data
📈
AI Sentiment
Highly Positive
8/10
ImmunityBio Inc. News
Latest updates and market news for IBRX
3 news
Jan 30 - Feb 5, 2026
Page 1
MT Newswires
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas
➖
AI Sentiment
Neutral
5/10
Business Wire
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
📈
AI Sentiment
Highly Positive
9/10
Share this news page